LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study

Tender description

LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study Lot 1: LUV00996 The provision of services for formulation development, clinical batch manufacture and distribution of the active pharmaceutical ingredient (API), Resveratrol: the COLO-PREVENT study. COLO-PREVENT will assess whether intervention with the API resveratrol is able to affect recurrence of colorectal adenomas within the NHS Bowel Cancer Screening Programme. Award of contract is dependent on: a)prior receipt by the University of an award letter from the funder (CRUK) and b) a cap on the overall budget of £1,268,920 including VAT at 20%.